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The ability to awaken from sleep in response to important stimuli is a critical feature of
normal sleep, as is maintaining sleep continuity in the presence of irrelevant background
noise. Dual orexin receptor antagonists (DORAs) effectively promote sleep across species
by targeting the evolutionarily conserved wake-promoting orexin signaling pathway. This
study in dogs investigated whether DORA-induced sleep preserved the ability to awaken
appropriately to salient acoustic stimuli but remain asleep when exposed to irrelevant
stimuli. Sleep and wake in response to DORAs, vehicle, GABA-A receptor modulators
(diazepam, eszopiclone and zolpidem) and antihistamine (diphenhydramine) administration
were evaluated in telemetry-implanted adult dogs with continuous electrocorticogram,
electromyogram (EMG), electrooculogram (EOG), and activity recordings. DORAs induced
sleep, but GABA-A modulators and antihistamine induced paradoxical hyperarousal. Thus,
salience gating studies were conducted during DORA-22 (0.3, 1, and 5 mg/kg; day and
night) and vehicle nighttime sleep. The acoustic stimuli were either classically conditioned
using food reward and positive attention (salient stimulus) or presented randomly (neutral
stimulus). Once conditioned, the tones were presented at sleep times corresponding to
maximal DORA-22 exposure. In response to the salient stimuli, dogs woke completely
from vehicle and orexin-antagonized sleep across all sleep stages but rarely awoke to
neutral stimuli. Notably, acute pharmacological antagonism of orexin receptors paired with
emotionally salient anticipation produced wake, not cataplexy, in a species where genetic
(chronic) loss of orexin receptor signaling leads to narcolepsy/cataplexy. DORA-induced
sleep in the dog thereby retains the desired capacity to awaken to emotionally
salient acoustic stimuli while preserving uninterrupted sleep in response to irrelevant
stimuli.
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INTRODUCTION
Across the animal kingdom, the ability to awaken from sleep in
response to salient signals (e.g., predator, fire alarm) and maintain
sleep continuity in the presence of irrelevant background noise
(e.g., environmental noise, traffic noise) is clearly important for
both survival and healthy sleep. Auditory salience discrimination
during normal sleep is the ability to discern between emotionally
relevant versus irrelevant acoustic stimuli.
Classic studies in sleeping animals demonstrated that the
threshold for awakening to emotionally relevant acoustic stimuli
is much lower than the threshold for waking to an irrelevant
auditory stimulus (Buendia et al., 1963; Dillon and Webb, 1965;
Siegel and Langley, 1965; Van Twyver and Garrett, 1972; Langford
et al., 1974; Halperin and Iorio, 1981; Coenen, 2010). Early
laboratory studies involving the presentation of negatively con-
ditioned acoustic stimuli, such as a tone associated with a shock,
found animals more likely to awaken to these relevant conditioned
versus neutral acoustic stimuli (Buendia et al., 1963; Van Twyver
and Garrett, 1972; Halperin and Iorio, 1981). Such studies often
invoked an underlying evolutionary drive to awaken in response
to danger or predation signals with minimal disruption to sleep
continuity in the presence of non-meaningful sounds, with the
sleeping brain serving a sentinel function (see Snyder, 1966), as
the ultimate benefit of such salience discrimination during sleep.
Human experimental paradigms have also demonstrated that
sleeping people can exhibit an arousal response to salient acoustic
stimuli over less salient stimuli, such as arousing to recordings
of their own name over other names (Oswald et al., 1960;
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Langford et al., 1974; Coenen, 2010). Moreover, humans appear
capable of differentiating acoustic stimuli at sub-arousal levels, as
evidenced by oddball paradigm (Nordby et al., 1996), auditory
evoked potential (Perrin et al., 1999), and neuroimaging (Portas
et al., 2000) studies reporting that the sleeping brain can process
acoustic stimuli as in wakefulness and distinguish emotionally
relevant stimuli.
The threshold of arousal to acoustic signals in humans can
be affected by central nervous system (CNS) depressants, such
as benzodiazepines. In clinical studies, for example, flurazepam
increased the arousal thresholds of subjects to both neutral (elec-
tronic tone) and emotionally salient (recording of subject’s name)
acoustic stimuli (Mendelson et al., 1988). Similarly, triazolam
impaired the ability of subjects to awaken to smoke-detector
alarm signals (Johnson et al., 1987).
The orexin signaling pathway is conserved across mammalian
species and plays an important role in regulating arousal and
sleep (Sakurai et al., 1998; Gotter et al., 2012; Tsujino and
Sakurai, 2013). Dual orexin receptor antagonists (DORAs), that
block orexin receptors 1 and 2, have recently been developed
and promote sleep by decreasing wake signaling and thereby
enabling sleep (Brisbare-Roch et al., 2007; Winrow et al., 2011,
2012; Herring et al., 2012; Bettica et al., 2012b; Winrow and
Renger, 2014). In contrast, the mechanism of action of the
current standard of care for insomnia is mediated by positive
allosteric modulators of inhibitory γ-aminobutyric acid (GABA)-
A receptors (GABA-A receptor modulators). This mechanism
involves sleep promotion through the suppression of CNS activity
that can be associated with muscle relaxation, anxiolysis and
amnesia due to relatively more widespread receptor expression
(Nutt and Stahl, 2010; Tan et al., 2011). The question remains
as to whether DORAs, which inhibit orexin-mediated arousal
and wakefulness, promote sleep while maintaining the ability to
salience gate relevant versus irrelevant acoustic stimuli by either
waking or remaining asleep, respectively.
The present study used an auditory salience gating condi-
tioning paradigm to investigate whether DORA-induced sleep
preserved the ability of dog to wake in response to emotion-
ally salient acoustic stimuli but remain asleep when exposed
to irrelevant stimuli. Electronically generated acoustic stimuli
were classically conditioned using either food reward and posi-
tive attention (salient) or nothing (neutral). Once conditioned,
the acoustic stimuli alone were presented at times correspond-
ing to maximal compound exposure or at the same time dur-
ing natural (vehicle) sleep, and sleep/wake stages were assessed
through continuous telemeterized electrocorticogram (ECoG),
electromyogram (EMG), electrooculogram (EOG), and activity
recordings.
Dogs were chosen to address salience gating of acoustic stimuli
during DORA-induced sleep because their sleep and wake are
more consolidated than preclinical rodent models, they do not
exhibit sleep torpor, and they possess extremely sensitive auditory
discrimination capacity. In addition, orexin signaling clearly plays
a key role in the regulation of sleep in dogs as chronic loss of
orexin signaling due to genetic mutations in orexin receptor 2
causes canine narcolepsy (Lin et al., 1999; Nishino, 2007), while
temporary acute pharmacological blockade of orexin signaling by
DORA administration can induce sleep in dogs without signs of
narcolepsy/cataplexy (Brisbare-Roch et al., 2007; Winrow et al.,
2011, 2012).
Although DORAs produce a transient and reversible pharma-
cological blockade of orexin receptors, not a chronic loss of orexin
signaling across the lifespan as in dog narcolepsy, we also assessed
cataplexy with high-dose DORA administration in the standard
canine Food Elicited Cataplexy Test (FECT; see Babcock et al.,
1976). A preliminary FECT study was necessary to confirm that
classical conditioning of an acoustic stimulus with a salient food
reward would not potentially confound a study of awakening from
sleep, as strong emotional salience as seen with food anticipation
is a primary trigger of cataplexy in orexin-deficient narcoleptic
dogs (Babcock et al., 1976; Kushida et al., 1985; Nishino et al.,
1997).
Finally, since the veterinary literature qualitatively cites case
studies of accidental GABA-A receptor modulator and antihis-
tamine ingestion causing paradoxical hyperarousal in healthy
dogs (Barnett et al., 1984; Bertini et al., 1995; Richardson
et al., 2002; Wismer, 2002; Herron et al., 2008; Lancaster et al.,
2011), we quantitatively pre-tested several representative drugs via
polysomnography (PSG) to determine whether we could evaluate
different pharmacological hypnotic mechanisms in the salience
gating arousal paradigm.
In response to the salient conditioned acoustic stimuli, dogs
in the present study awoke completely from vehicle and orexin-
antagonized sleep across all sleep stages but rarely awoke to the
neutral stimuli.
MATERIALS AND METHODS
ANIMAL SUBJECTS
Adult male and female Beagle dogs (2–14 years old, 8–17 kg)
were singly housed for the study duration under standard indoor
laboratory conditions of controlled temperature, humidity, and
lighting (12-h light:12-h dark), with a single mid-day feed. Water
was provided ad libitum. All studies were conducted in accordance
with the Merck Institutional Animal Care and Use Committee and
the National Research Council’s Guide for the Care and Use of
Laboratory Animals.
DRUGS AND PHARMACOKINETICS
DORA-22 and DORA-12 were synthesized at Merck as previ-
ously described (Cox et al., 2010; Coleman et al., 2012; Winrow
et al., 2012). Representative GABA-A receptor modulators and
a histamine inverse agonist, which tend to promote sleep in
most species but have paradoxical hyperarousal effects in dogs
according to qualitative reports in the canine veterinary literature
(Barnett et al., 1984; Bertini et al., 1995; Richardson et al., 2002;
Wismer, 2002; Herron et al., 2008; Lancaster et al., 2011; Giorgi
et al., 2012), were also evaluated in the sleep studies as potential
control sleep-inducing substances for the salience arousal studies.
Diazepam was purchased from Sigma-Aldrich, eszopiclone from
Sunovion Pharmaceuticals, zolpidem from Teva Pharmaceuticals,
and diphenhydramine from Henry Schein. DORA-22 (0.3, 1,
5 mg/kg), DORA-12 (1 mg/kg), and eszopiclone (0.5, 5, 12 mg/kg)
were administered orally by gavage in 20% vitamin E tocopherol
polyethylene glycol succinate (TPGS); diazepam (1 mg/kg) and
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zolpidem (1 mg/kg) were administered orally by gavage in 0.5%
carboxymethylcellulose; and diphenhydramine (4 mg/kg) was
administered in saline (intramuscularly).
Pharmacokinetic assessments were performed to determine
plasma levels of the DORAs in study dogs approximately 1 week
after studies were completed to avoid confounding EEG and
behavioral assessments; DORAs were orally dosed in fasted dogs
as detailed above. Blood was collected from the femoral artery
in the presence of EDTA at 0.25, 0.5, 1, 2, 4, 6, and 24 h post-
dose, and the resulting plasma was stored frozen at −20◦C.
Plasma concentrations were determined by protein precipitation
followed by liquid chromatography–tandem mass spectrometry
in the positive ion mode using atmospheric pressure chemical
ionization. The lower limit of quantitation for both compounds
was 0.002 uM.
DOG PSG AND SLEEP STAGING
Dogs were implanted with subcutaneous telemetric devices
(D70-EEE; Data Sciences International) to record simultaneously
ECoG, EMG, EOG and locomotor activity using the surgical
procedure described previously (Winrow et al., 2011, 2012). All
implant surgeries were completed at least 6 months prior to study
initiation, with a minimum of 2 weeks after the most recent
subcutaneous battery-replacement procedure.
Sleep stages were evaluated using both continuous hand-
scoring (2–4 h surrounding dosing) and a customized ver-
sion of the sleep algorithm Somnologica (Embla Systems)
based on a combination of ECoG, EMG, and EOG activity
and movement within the field of the radiofrequency receiver,
as described previously (Winrow et al., 2011, 2012). Briefly,
ECoG/EMG/EOG/locomotion data were used to characterize four
sleep-wake stages in the dogs: active wake, slow wave I sleep
(lighter non-rapid eye movement [REM] sleep), delta II sleep
(deep non-REM sleep), and REM sleep. Sleep architecture data
were evaluated in 30-s epochs and then averaged into 30-min bins
across 24 h (sleep studies only).
SLEEP-WAKE STUDY DESIGN
All sleep-wake studies used a within-subject cross-over design
(vehicle × drug) with telemetric PSG recordings 24 h/day. In
DORA sleep studies (n = 6 male dogs/study; 5 days vehicle ×
5 days drug), dogs were dosed at Zeitgeber time (ZT) 03:00
(daytime studies) to represent the active period and at 1 h prior
to lights out (ZT 11:00 for nighttime studies, DORA-22 only)
to align peak efficacy during lights-out without waking the dogs
for dosing. In the GABA modulator/antihistamine sleep studies
(n = 6–7, 1–3 days vehicle × 1–3 days drug), dogs were dosed at
ZT 03:00.
FOOD ELICITED CATAPLEXY TESTS (FECT)
Daytime FECTs (n = 11; 6 males, 5 females) (Babcock et al.,
1976; Kushida et al., 1985; Nishino et al., 1997) with simultaneous
video and ECoG/EMG/EOG recordings were conducted with
vehicle (n = 2 tests/dog) and DORA-12 (n = 2 tests/dog). DORA-
12 has been previously shown to promote sleep, and the dose
selected robustly decreases wakefulness in dogs (>100-fold min-
imum efficacious sleep dose; see below). FECTs were conducted
approximately 45–60 min post-dose in an empty room to which
animals were habituated prior to testing, as described in the FECT
literature (Babcock et al., 1976; Kushida et al., 1985; Nishino et al.,
1997). Briefly, each dog was singly released into the test room and
remotely monitored while consuming 10 approximately 1 inch2
balls of wet dog food (Pedigree® chunk beef), which were evenly
spaced one foot apart down the middle of a clean disposable
absorbent pad placed on the floor. Video and ECoG/EOG/EMG
recordings were evaluated for any signs of cataplexy (e.g., collapse,
EMG attenuation, sudden-onset REM sleep; see Kushida et al.,
1985) and the time to consume all 10 balls of food.
SALIENCE AROUSAL STUDIES
Dogs (n = 6–8; 3–4 males, 3–4 females) were housed in two
separate rooms of 3–4 dogs each, equipped with a central auditory
speaker and video camera. Two novel, electronically generated
(Spike2 v5.2.1, Cambridge Electronic Design) distinct acoustic
stimuli of 700 Hz and 1000 Hz (50 dB, 3-s duration) were selected
based on the criteria that the tones’ decibel levels varied no more
than 3 dB between the interiors of each individual dog run. The
ambient noise level in the dog room was approximately 50 dB
at all times, without barking. The tones representing the neutral
stimulus (neutral) and salient positively reinforced, classically
conditioned stimulus (salient CS) were counterbalanced across
the rooms (e.g., Room 1 dogs: neutral = 700 Hz, salient = 1000 Hz;
Room 2 dogs: neutral = 1000 Hz, salient = 700 Hz).
Conditioning to the neutral stimuli occurred in the 6 weeks
prior to and for the duration of the arousal studies. During
this time, the neutral stimulus was played in the dog rooms
at randomly generated times in clusters of 3 tones/30 s (par-
allels 30 s epoch for sleep stage scoring), with an average of
3 clusters (9 tones) per hour, 0–15 h/day (maximum of 3 h/day
during lights out). Dogs were monitored by video (i.e., no behav-
ioral reaction) and by PSG (i.e., sleep fragmentation parameters
demonstrating equivalence of the neutral tone with the absence
of an acoustic stimulus; data not shown) prior to positive con-
ditioning of the salient tone and during the study to confirm
that the neutral stimulus was indeed neutral. See Figure 1.
FIGURE 1 | Salience-gated arousability paradigm in dogs. Dogs (n = 8)
were classically conditioned to anticipate nothing (Neutral) or food reward
with positive attention (Salient) following a 300 ms acoustical stimulus.
During salience testing, only the Neutral or Salient Conditioned Stimulus
(CS) tone were presented to sleeping dogs (2 tests/dog/condition); no room
entry or reward was given. Telemeterized polysomnography (PSG) was
used to quantify Active Wake or continued sleep in response to the
differently salienced stimuli.
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For 3 weeks prior to arousal study initiation, the salient acous-
tic stimulus was immediately reinforced with bites of wet food
(Pedigree® chunk beef) and positive attention, see Figure 1.
Food and attention were delivered by assistants who entered
the room immediately upon salient tone delivery; assistants
wore visually distinct lab coats and had never been involved
in the dogs’ dosing, blood sampling, surgery, or cage clean-
ing. The salient tone was played randomly in clusters of
1–3 tones/3 min, each followed by 30 s of reinforcement, 0–2
times/day (daytime and lights out). Approximately 1 h prior
to a salient tone reinforcement session (0–2 times/week), the
dogs were dosed with saline to ensure that dosing did not
inadvertently become a contextual cue during the actual study.
Positive reinforcement of the salient stimulus continued 1–
3 times/week for the study duration. Prior to and during the
arousal study, dogs were monitored by video to confirm that
the salient CS was indeed salient (e.g., the tone elicited imme-
diate visual orientation to the human entry door, barking, and
jumping).
During the arousal study trials, only the neutral and salient
acoustic tones were played; no reinforcement followed the salient
stimulus (Figure 1). Continuous video and ECoG/EMG/EOG
recordings occurred before, during, and after stimulus presen-
tation. Animals were dosed with either vehicle (night testing
only) or DORA-22 (0.3, 1, 5 mg/kg; doses were randomized)
approximately 30–60 min prior to a stimulus presentation, with
0–1 test per day. Dogs received both one neutral 3-tone/30-s
cluster and one CS 3-tone/30-s cluster during each day’s test
(counterbalanced order, separated by 15–30 min). Tone presen-
tation was simultaneously digitally marked on the PSG recording
trace using DSI software. Each dog was ultimately tested twice
per DORA-22 dose: once with the neutral stimulus first, and
once with the CS stimulus first. Dogs received four counterbal-
anced vehicle-only night control tests. Vehicle treatment was not
assessed in the daytime studies because the dogs were not typically
asleep.
Data from individual tests were excluded if the dog’s PSG
recordings did not confirm sleep during the 2 min immediately
preceding the stimulus tone. Arousal was defined as at least a
single 30-s epoch of PSG-defined “Active Wake” beginning with
the epoch containing the three stimulus tones.
DATA ANALYSIS
Overall, the cross-over design studies utilized either a repeated
measures analysis of variance or paired two-tailed t-tests. All data
are reported as the mean per animal (across days or tests) and the
variability (standard error of the mean).
An independent mixed-model analysis was applied for the
multi-day 24-h sleep architecture results for each 30-min time
bin versus vehicle averaged per animal across days, as described
previously (Winrow et al., 2011). In the PSG comparison stud-
ies, the mean cumulative time in active wake for each dog
during the first 2 h after compound dosing was expressed as
the percentage change from vehicle administration. A two-tailed
population t-test was used to assess the change in wake for
each compound compared with 0 (no change in wake from
vehicle).
RESULTS
DORA PHARMACOKINETICS
DORA-12, used to maximize exposure for the FECT, at 1 mg/kg
produced peak plasma concentration levels (Cmax) of 1.63 µM ±
1.3 with a 24-h drug exposure value (area under the curve; AUC)
of 9.52µMh. DORA-12 plasma exposure peaked (Tmax) at 0.5 h±
0.0. During the FECT studies, the plasma levels at 1–2 h post-
dose were approximately 1.5 µM, which is >100-fold higher than
minimum efficacy exposure levels tested for this compound to
induce sleep in adult dogs (an approximately 30% decrease in
wake was observed with Cmax = 0.014 µM ± 0.008 and AUC =
0.07 µMh).
DORA-22, used in the arousal studies, exhibited dose-
responsive plasma pharmacokinetic levels across 0.3 mg/kg
(Cmax = 0.26 µM ± 0.07, AUC = 0.63 µMh ± 0.1), 1 mg/kg
(Cmax = 0.91 µM ± 0.08, AUC = 3.87 µMh ± 0.2), and 5 mg/kg
(Cmax = 3.02 µM ± 0.5, AUC = 12.65 µMh ± 2.5), a 20-fold
range of exposure. Tmax values were relatively constant across
doses: 0.7 h, 0.7 h, and 0.5 h, respectively, which approximately
corresponded to the time of acoustic stimulus presentation in the
salience arousal studies.
SLEEP-WAKE
No GABA-A receptor modulator tested produced a sleep
effect in dogs when administered during the day; diazepam,
eszopiclone and zolpidem all had significant paradoxical hyper-
arousing effects, as did the antihistamine diphenhydramine
(Figure 2). These results are consistent with ad hoc reports
in the canine veterinary literature (Barnett et al., 1984;
Bertini et al., 1995; Richardson et al., 2002; Wismer, 2002;
Herron et al., 2008; Lancaster et al., 2011; Giorgi et al.,
2012). However, daytime administration of DORA-22 signifi-
cantly decreased active wake (Figure 2). Vehicle-treated night-
time sleep in dogs, therefore, was selected as the sole sleep
comparator for DORA-22 sleep in the salience arousal paradigm
FIGURE 2 | DORA-22 promotes sleep in beagle dogs. GABA-A receptor
modulators (eszopiclone and zolpidem) and antihistamine
(diphenhydramine) produce paradoxical hyperarousal but DORA-22 induces
sleep in dogs. Only DORA-22 was thereby assessed for salience-gated
arousability and compared to unmedicated healthy sleep in dogs. Data
expressed as mean percentage change ± SEM from vehicle during the first
2 h post-dose during the daytime active period. * p < 0.05; ** p < 0.01;
*** p < 0.001.
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FIGURE 3 | Dog sleep architecture with DORA-22 dosed during
daytime (left) or prior to night lights-out (right). DORA-22 (open
circles; 5 mg/kg) and vehicle (20% Vitamin E TPGS, closed circles) were
administered to the same dogs (n = 6) in a balanced cross-over design.
Data are presented as mean per dog over 5 days of consecutive treatment
per 30-min epoch ± SEM. Arrows, dosing; dashed line, feeding (daytime);
gray vertical lines and tic marks (short, medium, long: p < 0.05; p < 0.01;
p < 0.001, respectively).
as the other potential hypnotics did not produce sleep in
the dog.
The sleep architecture underlying the decrease in active wake
with administration of the DORA-22 5 mg/kg (n = 6) dose
used in the daytime and nighttime sleep trials is presented in
Figure 3. During daytime administration, DORA-22 significantly
decreased active wake, and significantly increased slow wave sleep,
delta sleep, and REM, all relative to the vehicle control, to approxi-
mately nighttime levels. DORA-22 administered 1 h prior to lights
off (night period) decreased active wake and increased sleep at the
time of dosing; after lights off, DORA-22 sleep paralleled vehicle
nighttime sleep architecture.
FOOD ELICITED CATAPLEXY TEST
No male or female dog showed any behavioral or EMG-
characteristic signs of cataplexy during the FECT study; the dogs
were continuously in active wake (by video and PSG assessment)
through the completion of all food consumption. Overall, the
duration to complete the FECT did not differ between the vehicle
and drug tests for all dogs (t(10)= 0.41, p = 0.69) (Figure 4). The
percentage change per dog between time to complete the FECT
with vehicle and DORA-22 did not differ from zero (t(10) = 0.20,
p = 0.86).
SALIENCE AROUSAL STUDIES
When tested during the nighttime (lights-out) period, vehicle-
treated male and female dogs awoke from sleep significantly more
often to the salient CS tone than to the neutral tone (t(16) = 8.85,
p < 0.0001; Figure 5A). With regard to DORA-22-induced day-
time sleep, dogs woke significantly more to the salient CS tone
FIGURE 4 | Time to complete Food Elicited Cataplexy Test (FECT) was
not affected by high-dose DORA-12. Dogs showed no physical signs of
cataplexy (see Babcock et al., 1976) and there was no difference in the
mean duration (seconds/dog/2 tests ± SEM) to complete FECT on vehicle
(20% Vitamin E TPGS; black) compared to the same dogs (n = 11) with
high-dose DORA-12 (1 mg/kg, 100x minimum efficacious sleep dose; white)
tested at peak exposure.
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FIGURE 5 | Dogs awoke to the conditioned salient stimulus and slept
through the neutral stimulus. Percentage of dogs (n = 6–8) aroused into
Active Wake during (A) unmedicated (20% Vitamin E TPGS vehicle) night sleep,
(B) DORA-22-induced daytime sleep, and (C) DORA-22-induced night sleep
with the neutral acoustical stimulus and salient conditioned stimulus (CS).
Mean percentage per dog across 2 tests/condition ± SEM. ***p < 0.0001.
than to the neutral tone for all DORA-22 doses tested (F(1,14) =
2209, p < 0.0001; each dose neutral-salient post-hoc comparison
p < 0.0001; Figure 5B). In the night sleep trials, dogs again
woke significantly more from DORA-22-induced nighttime sleep
in response to the salient CS tone than to the neutral tone for
all doses tested (F(1,14) = 2209, p < 0.0001; each dose neutral-
salient post-hoc comparison p < 0.0001; Figure 5C). Although
each test was comprised of a cluster of 3 tones within a 30-s epoch,
all arousals occurred in response to the first tone. There was
no overall dose effect or interaction between dose and acoustic
stimulus.
Across all studies, sleep stage did not predict whether a dog
responded or did not respond to an acoustic stimulus. In response
to the salient CS tone, dogs awoke from all sleep stages (Table 1).
Dogs remained asleep when the neutral tone was presented at
all sleep stages, although there was a modest trend in the sleep
architecture for the animals to shift from a deeper sleep stage to a
lighter sleep stage (Table 1). The single occurrence of continued
sleep in response to the salient CS tone (vehicle, night test) was
during slow wave I sleep. Three cases of arousal to the neutral
stimulus (one each with vehicle and DORA 0.3 mg/kg, night test,
and one with DORA 1 mg/kg, daytime test) occurred during delta
II or REM sleep.
Figure 6 shows examples of PSG traces from a single dog
treated with DORA-22 1 mg/kg during the day, and exposed to
Table 1 | Arousal or continued sleep in response to acoustic stimuli by
sleep architecture stage.
Slow wave I Delta II REM
Salient conditioned 31.7% 58.5% 9.8%
stimulus—awoke†
Immediately before 43.5% 46.5% 10.0%
neutral
Neutral stimulus— 52.5% 40.0% 7.5%
continued sleep‡
The distribution is presented as the percentage of all tests per condition and
result.
†One vehicle-treated dog did not wake with the salient conditioned stimulus
(slow wave I sleep);
‡one vehicle- and two DORA-treated dogs were aroused with the neutral tone
from delta II (n = 2) and REM sleep (n = 1).
neutral and CS acoustic stimuli. In both examples, the animal is
asleep prior to the first tone presentation. With the neutral tone
presentation, the dog remains in slow wave I sleep. Note that a
brief perturbation may be seen in the ECoG trace at the time of the
first neutral tone, yet the animal remains asleep. In contrast, with
the presentation of the first salient CS tone, the dog immediately
transitions from delta II sleep to active wake, as reflected in the
ECoG, EMG, EOG, and locomotor traces.
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FIGURE 6 | A sample PSG trace during DORA-22 presentation of a neutral
(left) and salient conditioned (right) stimulus. Thirty-second sample of
PSG (ECoG, EMG, EOG, and locomotor activity) traces for a dog (subject
10-0451) approximately 45 min after receiving DORA-22 1 mg/kg oral daytime
dosing in response to neutral (left) and salient conditioned (CS, right) acoustic
stimuli presentation (arrows). Note that the dog remains asleep during the
neutral tone (only ECoG perturbation), but immediately awakens into Active
Wake with the salient CS tone. The first 2 tones of a 3-tone/30-s epoch are
shown. AW, active wake; ECoG, electrocorticogram; EMG, electromyogram;
EOG, electrooculogram; SWSI, slow wave I sleep; delta II, delta II sleep.
DISCUSSION
The present study used an auditory salience gating condition-
ing paradigm in dogs to investigate whether DORA-induced
sleep preserved natural sleep’s ability to awaken appropriately
to emotionally salient acoustic stimuli but remain asleep when
exposed to irrelevant stimuli. The PSG data confirmed dose-
responsive sleep-promoting effects of orexin antagonism in dogs.
When administered during the daytime or just prior to nighttime
lights off, DORA treatment did not impair the ability to respond
selectively to emotionally salient acoustic stimuli: at all doses and
times, dogs aroused to emotionally salient acoustic stimuli but
slept through neutral acoustic stimuli. The dogs’ salience gating
ability during DORA-induced sleep was identical to salience gat-
ing during natural (vehicle) nighttime sleep.
Dogs exhibit a conserved, translatable, and reliable orexin
antagonist-associated sleep response (Brisbare-Roch et al., 2007;
Winrow et al., 2011, 2012) not observed with GABA-A modulator
hypnotics or an antihistamine known to have sedating proper-
ties in humans. The present study quantitatively confirmed dog
paradoxical hyperarousal reported with accidental ingestion of
these agents (Barnett et al., 1984; Bertini et al., 1995; Richardson
et al., 2002; Wismer, 2002; Herron et al., 2008; Lancaster et al.,
2011; Giorgi et al., 2012). In contrast, daytime and before night-
time DORA administration significantly and dose-responsively
decreased the amount of time spent in active wake and increased
slow wave, delta and REM sleep to parallel normal nighttime
sleep architecture distribution and percentages, consistent with
the effects of structurally diverse DORAs reported by a num-
ber of groups in dogs and other sleep models and in humans
(Brisbare-Roch et al., 2007; Winrow et al., 2011, 2012; Bettica
et al., 2012a,b; Fox et al., 2013). DORA administration may
thus represent the only non-anesthesia pharmacological method
currently known to reliably induce sleep in dogs. However, due
to the lack of somnolence-inducing effects of GABA-A receptor
modulators or antihistamine in dogs, this model was unable to
compare directly salience gating during sleep induced by these
classes of drugs with natural and DORA-induced sleep. The
mechanism underlying these paradoxical effects in canines are
currently unknown, but may involve dog-dependent differences
in the balance of GABA-A and orexin-mediated signaling in
promoting sleep and arousal, respectively (Saper et al., 2005).
Additional studies in other mammalian sleep models and humans
may allow for such comparisons of the differences in salience
gating between DORA and GABA-A modulators, as well as poten-
tially elucidate the neural circuits underlying differences among
species.
DORA administration was negative in FECT, and the time
required to complete the FECT for vehicle- and DORA-treated
dogs in this study was consistent with that reported for normal
dogs (within 45 s; Babcock et al., 1976). The lack of effect of
DORA administration in the FECT suggests that acutely antag-
onizing an intact orexin system in normal dogs differs from
the pathological chronic condition of genetic orexin depletion
in narcoleptic dogs. These data are consistent with previous
studies demonstrating that orexin antagonism does not reca-
pitulate the phenotypes of genetic orexin deficiency (Chemelli
et al., 1999; Lin et al., 1999; Brisbare-Roch et al., 2007; Winrow
et al., 2011, 2012; Mang et al., 2012). Perhaps even more strik-
ingly along this acute versus chronic orexin-depletion dichotomy,
the type of strong emotionally salient stimuli—food—that typ-
ically induces sleep-like cataplexy in orexin-deficient narcolep-
tic dogs during the FECT is the same CS association that
caused DORA-treated dogs to awaken from sleep in the present
study.
It has been established that the emotional significance of
a stimulus is associated with the ability to induce an arousal
response from natural sleep, as demonstrated by early sleep
experiments in rodents (Van Twyver and Garrett, 1972), cats
(Buendia et al., 1963; Siegel and Langley, 1965), and humans
(Oswald et al., 1960; Langford et al., 1974). Consistent with
the historical literature, the DORA- and vehicle-treated dogs
in this study awoke completely in response to the emotionally
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salient conditioned tone presentation but were not aroused
by similar tones played randomly without conditioning. These
results clearly indicate that neither discrimination between neu-
tral and salient stimuli nor the arousal in response to salient
stimuli is dependent upon orexin, but likely a downstream
mechanism. More work will need to be done to investigate
the mechanism of acute arousal, but potential explanations
beyond the scope of the current work include the disinhibi-
tion of GABA tone, downstream pathways affecting histamine
release or other, yet to be defined pathways affecting CNS
arousal.
Some studies in other sleep models have reported differences
in arousability from different sleep stages, and while REM sleep
was originally hypothesized to be associated with increased vig-
ilance, this has not been confirmed experimentally (Siegel and
Langley, 1965; Snyder, 1966). In the current dog studies, the
PSG analyses indicated that vehicle- and DORA-treated dogs were
similarly able to awaken from all sleep stages in response to the
conditioned acoustic stimulus, without a predictive effect of sleep
stage on arousability. It remains possible, however, that a larger
sample size may reveal salience arousability differences among
sleep stages.
In working with dogs, a specific decision was made in the
present study to use a positively conditioned salient stimulus
instead of a negatively CS (e.g., shock), as has often been used in
the salience arousal literature. The orexin peptides, particularly
Orexin-A, are known to be associated with increased feeding
behaviors in animals, whereas orexin antagonism is reported to
decrease eating (Sakurai et al., 1998; Haynes et al., 2000; Rodgers
et al., 2000; Tsujino and Sakurai, 2013). Accordingly, we risked
having the DORA effects blunt the salience of a food-associated
CS. Although we cannot directly address any modulating impact
of DORAs on the salience of the food-conditioned stimulus,
at the very least the CS was sufficiently salient to distinguish
it from the neutral cue. Video recordings during the arousal
testing subjectively confirmed animal excitation upon presenta-
tion of the salient stimulus during both the vehicle and DORA
trials. Meanwhile, the predominant use of negatively conditioned
stimuli in studies of salience gated arousal in natural sleep in
the historical animal literature (Buendia et al., 1963; Siegel and
Langley, 1965; Van Twyver and Garrett, 1972) gives confidence
that negative stimuli may also be associated with differential
increases in arousal during DORA-induced somnolence.
Further investigations of salience discrimination during
DORA-induced sleep in additional models and humans are war-
ranted, as this new class of insomnia agent may have the potential
to allow patients to sleep undisturbed by benign stimuli (e.g., traf-
fic noise, partner snoring) but not miss responding to important
signals (e.g., smoke detector, intruder).
CONCLUSION
As with natural sleep, dogs administered DORAs retained the
ability to distinguish between irrelevant auditory sounds and
important cues and responded by remaining asleep or waking
up from all sleep stages, respectively. The results from this study
further reinforce the notion that acute DORA treatment dif-
fers from the endogenous developmental low orexin levels in
narcoleptic dogs in that DORA treatment resulted in normal
sleep architecture, lack of signal in the FECT, and response to an
emotionally salient stimulus with immediate awakening instead of
cataplexy. It is perhaps fitting, therefore, that while the role of the
orexin peptide was originally elucidated in dogs, DORA-induced
sleep may be the only reliable method aside from anesthesia to
potentially come full circle and pharmacologically induce sleep in
dogs. Finally, maintaining salience-specific arousal is yet another
way DORAs have the potential to differentiate from existing
insomnia agents.
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